在开发HIV-1疫苗方面面临的挑战
1Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA. dbarouch@bidmc.harvard.edu
Nature
|October 4, 2008
概括
开发一种有效的人类免疫缺陷病毒 (HIV) -1 疫苗仍然是全球卫生优先事项. 目前的候选疫苗尚未成功,需要进一步研究和开发可行的HIV-1疫苗.
科学领域:
- 免疫学 免疫学 免疫学
- 疫苗学 疫苗学 疫苗学
- 全球健康 全球健康
背景情况:
- 开发一种安全有效的人类免疫缺陷病毒 (HIV) -1 疫苗是关键的全球卫生优先事项.
- 尽管在HIV-1病原和免疫学方面取得了进展,但仍然存在重大科学挑战.
- 现有的HIV-1候选疫苗在临床试验中没有证明对感染的保护或病毒载荷的减少.
研究的目的:
- 审查预防性HIV-1疫苗开发的关键挑战和未来前景.
- 突出需要重新致力于基础研究,临床前研究和临床试验.
主要方法:
- 关于HIV-1疫苗开发的当前科学文献的综述.
- 对引发有效的幽默和细胞免疫反应的挑战进行分析.
- 讨论未来的研究方向和前景.
主要成果:
- 原型HIV-1疫苗候选人未能在临床疗效研究中获得保护.
- 主要的科学障碍继续阻碍开发成功的HIV-1疫苗.
结论:
- 对基础发现研究,临床前研究和临床试验的协调承诺至关重要.
- 克服目前的障碍需要在HIV-1疫苗开发领域进行新的和协调的努力.
更多相关视频
13:36Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
Published on: May 6, 2015
10:58Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
Published on: August 21, 2019
相关概念视频
Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Viral Mutations
A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material for adaptive...
Development of Immunocompetence
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Immunodeficiency Diseases
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...
There are three main causes of immunodeficiency disorders...
Vaccine Production
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
